In addition, doxorubicin co-administered with cisplatin (the latter not used in our study) upregulates PD-L1 expression in breast cancer (69) and PD-L1 inhibition in combination with IL-2 has synergistic effects on CD8+ T cells, suggesting that these two therapies may activate converging pathways (70). The gene discussed is CD8A; the disease is breast carcinoma.